Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Akari Therapeutics stock opened at $3.60 on Monday. Akari Therapeutics has a twelve month low of $2.81 and a […]